Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

sipuleucel-T

- PMLiVE

NICE set to knock-back Amgen’s myeloma treatment Kyprolis

Cites uncertainty in clinical and cost-effectiveness analyses

- PMLiVE

NICE backs expanded use of Brilique in final guidance

AZ’s maintenance therapy recommended for long-term use, post-heart attack

- PMLiVE

NICE backs Eisai’s Halaven for breast cancer

Reverses 2012 rejection due to new data and patient access discount

- PMLiVE

NICE set to reject Merck’s Erbitux for head and neck cancer

Draft guidance rules the treatment does not provide value for money

- PMLiVE

Pfizer dropping bococizumab casts shadow over PCSK9 class

US payer resistance and diminishing efficacy prompt decision on would-be blockbuster

- PMLiVE

EMA starts review of Pfizer and Merck’s PD-L1 inhibitor

Avelumab looks set to be the first new drug to treat Merkel cell carcinoma

National Institute for Health and Care Excellence NICE logo

NICE backs Amicus Therapeutics’ Galafold

Recommends oral alternative for treating Fabry disease

- PMLiVE

Study finds no problems switching from Remicade to biosimilar

Findings look to dispel ‘biosimilar resistance’ and encourage greater uptake

- PMLiVE

Pharma ‘could do better’ on social media engagement

Industry is comfortable with the tech but has work to do on its approach

- PMLiVE

After delay, Merck gets US approval for serious infection drug

Zinplava anticipated to accrue $300m in sales by 2020

Bristol-Myers Squibb (BMS) building

NICE U-turn on Opdivo for kidney cancer

BMS sways the watchdog with new data and a patient access scheme

- PMLiVE

J&J’s Caruso bullish on Remicade defence plans

Believes top-selling arthritis treatment will weather introduction of biosimilars in US market

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links